Welcome to the
European Biotechnology Network!
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.
The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.
Read more about our activities here.
Green light for biosimilar switching26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.The Latest Catch is brought to you by European Biotechnology News
While small molecule meds can oftentimes be freely switched for generics on the pharmacy level, regulators have been reluctant to allow for the same level in interchangeability as regards biologics. In fact, until now most countries have advised physicians to keep patients on one biologics brand entirely. The Finnish regulator is now the second to have slackened the rules. “The current position of Fimea is that biosimilars are interchangeable with their reference products under the supervision of a healthcare person.” According to them, there is sufficient evidence that switching from one version of a biologic to another is unproblematic. Risk of adverse effects can be expected to be similar to the risk associated with changes in the manufacturing process of any biological product.
The Dutch Medicines Evaluation Board MEB had already revised its position in March. While it had previously advised that patients on one biologic brand should stick to it, they now say that there is no problem with switching to another biologic version. However, the MEB’s position stipulated that the patient must be informed and remain under proper clinical monitoring.
Biosimilars still range far from generics in terms of interchangeability. “Automatic substitution at the pharmacy level is not within the scope of his recommendation,” the Fimea stresses.
Time will tell whether other countries in Europe will now reconsider their own stance on this sensitive topic.
Our Corporate Members are
European Biotechnology Network AISBL
Rue de la Science 14b
1040 Brussels, Belgium
Tel: +32 27 33 72 37
Join the European Biotechnology Network!
Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.